Latest Clinical Trials News

Noxopharm Limited has been granted its first US patent for the Sofra™ technology platform, marking a key milestone in its cancer immunotherapy research. This patent protects the company’s innovative immune-modulatory oligonucleotides, underpinning its expanding pipeline in a rapidly growing market.

EMVision Medical Devices has closed its $2 million Share Purchase Plan ahead of schedule due to strong investor demand, signaling robust market interest in its neurodiagnostic technology.

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.

Imagion Biosystems has made significant strides toward filing an IND application for its MagSense® HER2 breast cancer imaging agent, supported by positive FDA feedback and a recent $3.5 million capital raise to fund upcoming clinical trials.

PYC Therapeutics has kicked off a global Phase 1b repeat dose study of its investigational drug PYC-001 targeting Autosomal Dominant Optic Atrophy, a rare genetic eye disease with no current treatments. Initial dosing has begun, with key data expected in the second half of 2026.

Neurizon Therapeutics has been granted a key Australian patent for its lead drug candidate NUZ-001, extending protection for treatments targeting ALS, Alzheimer's, and other neurodegenerative diseases through 2041. This milestone complements earlier US patent grants and sets the stage for upcoming clinical trials.

Nexsen Limited has initiated clinical trials for its StrepSure® GBS Rapid Sensor, a next-generation diagnostic device aimed at improving maternal health outcomes. The trial's success could pave the way for regulatory approval and early market penetration by the second half of 2026.

Radiopharm Theranostics has announced a $40 million equity raise via a two-tranche placement and a Share Purchase Plan (SPP) to fund its clinical programs and working capital. The offer includes new shares at $0.03 each with free attaching options, subject to shareholder approval.

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.

PolyNovo Limited reported a robust 33.3% increase in Q1 FY26 sales, driven by strong U.S. growth and a remarkable surge in NovoSorb MTX sales. The company also completed key infrastructure projects, positioning itself for further expansion.

Neuren Pharmaceuticals has secured FDA Fast Track designation for its drug NNZ-2591 targeting Phelan-McDermid syndrome, accelerating its path through clinical development. This milestone underscores the urgent need for treatments in rare neurodevelopmental disorders.